Navigation Links
Arpida Interim Results for six Months to 30 June 2007
Date:8/28/2007

ere placed with institutional investors via an accelerated bookbuilding transaction. The shares were placed at CHF 30.50 per share, resulting in gross proceeds of CHF 51.9 million. Net proceeds (after expenses and taxes) were CHF 49.8 million.

The annual general meeting of shareholders of 8 May 2007 approved the appropriation of the accumulated loss in the Statutory accounts. The accumulated Statutory loss of CHF 31.1 million was compensated with an equal amount of share premium in the general reserves. This concerns a movement within equity and has no impact on the total amount.

Outlook

Based on current expectations and including pre-launch activities, NDA preparation and the recently announced development plans, cash used in operating activities in the second half of the year is forecast to remain around the level of the first half.

Shareholder structure

During the first half of 2007, the total number of common shares outstanding rose by 12.1% to 19.3 million. The increase was due to the placing of March, involving 1.7 million new shares from the authorised capital. In addition, 0.4 million shares were issued from conditional capital due to the exercise of staff options. Early August 2007, the number of outstanding shares increased by an additional 0.3% in connection with the payment related to the closing of the TLT transaction.

As per 28 August 2007, Arpida has four shareholders with stakes above 5%: Fidelity (10.7%), Deutsche Bank (10.1%), Schroders (7.8%) and Capital Group (5.0%). In accordance with SWX Swiss Exchange these stakes are considered free-float, which consequently is 100%.

Pipeline Development

Intravenous iclaprim in cSSSI Phase III programme completed

In February 2007, Arpida reported positive results of a Phase I trial with intravenous iclaprim in volunteers with varying degrees of renal and hepatic impairment and obesity. The predictable pharmacokinetics observed in these populations would su
'/>"/>

SOURCE Arpida
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
4. How Best Buy said bye to burnout, hello to results
5. Economic survey reveals better 2006 results
6. Third Wave Reports Third-Quarter Financial Results
7. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
8. Midwest small-cap life sciences turn in mixed third-quarter results
9. To boost advertising results, consider improving your web site
10. RedPrairie Reports Strong Results
11. 2003 Biotech Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that executives ... in the month of September.  , ... at Rodman & Renshaw,s 17th Annual Global Investment Conference ... at the St. Regis Hotel in New ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... in three years, the Best of State Program,s, ... company in the Medical Innovation category, , , ... LLC (ABL), developer of a new class of products based on ... has won the 2009 Utah Best of State award in the ...
... SAN DIEGO, June 5, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... scheduled to present at the 8th Annual Needham Life Sciences Conference ... Pacific Time) at the New York Palace Hotel in ... Chief Financial Officer, is scheduled to provide an overview of the ...
... Expansion in Medical Imaging Management , For Hospitals, ... June 4 Optimal Reading Services Group, Inc., a ... hospitals, imaging centers and radiology groups, announced today that ... substantial investment in Optimal. The investment provides Optimal with ...
Cached Biology Technology:American Biotech Labs(R) Garners 2009 Utah Best of State Award 2American Biotech Labs(R) Garners 2009 Utah Best of State Award 3Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 2Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 3Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... form of nanoparticles has been designed by Northwestern Medicine scientists to ... on cancer. This is the first cancer drug tested while in ... test. The scientists designed ... a chemotherapy drug to fertility and can be easily used to ...
... Scientists at the University of Liverpool are embarking on a ... warming on the ecosystems of the seas surrounding North West ... that shelf-seas the seas surrounding continental land masses - ... warming of the seas might affect it. The study ...
... University of Florida study of nearly 5,000 Haiti bird ... arrival 6,000 years ago didn,t cause the island,s birds ... became displaced during a mass extinction event following the ... evidence shows some species were more resilient than others. ...
Cached Biology News:New chemo drug gentler on fertility, tougher on cancer 2New chemo drug gentler on fertility, tougher on cancer 3Scientists awarded £3M to study the way Northwest European seas absorb carbon 2UF fossil bird study on extinction patterns could help today's conservation efforts 2UF fossil bird study on extinction patterns could help today's conservation efforts 3
solute carrier family 25, member 13 (citrin)...
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
CREB-2 (H-290)...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: